Mucoviscidose touches one in 20 Belgians as carriers, with a new diagnosis occurring every ten days through dual-parent gene transmission.
Genetic mutations disrupt water regulation in cellular mucus layers, creating thick blockages across pulmonary and pancreatic ducts. This physiological failure triggers recurrent respiratory infections alongside severe digestive complications.
Carrier frequency remains high across the population despite the condition being classified among rare diseases. Two thousand distinct mutations are currently cataloged and divided across six specific functional groups.
The predominant genetic alteration identified within patient registries is the Delta F508 mutation. Comprehensive therapeutic management requires managing a decade of evolving pharmaceutical interventions and strict reimbursement structures overseen by national authorities.
The market changed when Kalydeco (ivacaftor) entered the domestic market, serving as a potentiator designed to assist the CFTR protein channel. That initial treatment liquefied obstructive mucus to hydrate pulmonary tissues, according to reporting by L’Avenir.
“It is effective: it improves FEV1 (maximum respiratory capacity measured in one second) by 12 percent, but it is intended for a very small number of patients with very specific mutations… 36 people, said Stefan Joris, director of the Muco Association, to L’Avenir.”
Belgian Reimbursement of Cystic Fibrosis Medications Evolved over Years
European authorization for Orkambi arrived in 2015, but Belgium delayed public reimbursement until 2021. Symkevi entered clinical use alongside Orkambi during this era, though neither matched the primary efficacy metrics established by earlier therapies.
With an improvement of 3 to 4 percent in FEV1, Orkambi and Symkevi were less effective than the first treatment, the Kalydeco, but they could help 500 patients, Joris told L’Avenir.
National health insurance coverage expanded in 2022 when the INAMI approved Kaftrio for local patients. This fourth medication improved respiratory function by 12 percent while covering widespread mutations.
It was already applicable to 700 to 800 people because it covered the most common mutations, such as F508-TEL, Joris recalled to L’Avenir.
Alyftrek Expands Coverage Despite Remaining Gaps for Some Patients
Reimbursement policies shifted again on October 10 with the inclusion of Alyftrek into the national framework. This new therapeutic option delivers performance comparable to Kaftrio while successfully broadening coverage to include rare genetic variations.
Compared to Kaftrio, efficacy is similar, but it applies to more people, also encompassing rare mutations, Joris told L’Avenir. Thanks to it, 80 to 85 percent of people with cystic fibrosis benefit from modulator therapy.
Despite these pharmacological advances, approximately 15 percent of patients remain excluded from current modulator access programs. The Muco Association continues its advocacy to lower the minimum age threshold for pediatric reimbursement.
Kaftrio is reimbursed starting at age two, but for other treatments, you have to wait until the age of six, while young children sometimes have a serious state of health that requires the new treatments, Joris told L’Avenir.
Contraindications and When to Consult a Doctor
Some patients experience liver problems and must stop treatment because the damage becomes too significant.
Patients may also experience problems with anguish and anxiety during treatment cycles. In children, the treatment can cause kidney damage.
Patients forced to discontinue modulator therapies must revert to traditional symptomatic care protocols. Symptomatic management alleviates immediate discomfort but fails to halt the underlying progression of the disease.
Individuals who undergo pulmonary transplantation lose clinical eligibility for modulator therapies because the transplanted lungs are healthy, possessing different DNA and not developing the condition. However, mucus accumulation persists within the digestive system and the ear, nose, and throat area.
The interest of the new treatments in preserving organs other than the lungs must be highlighted, and studies must be carried out showing how these medications react with immunosuppressants, the Muco Association summarizes.
| Medication | Reimbursement Year | FEV1 Improvement | Patient Population Impact |
|---|---|---|---|
| Kalydeco (Ivacaftor) | 2016 | 12% | ~36 patients |
| Orkambi / Symkevi | 2021 | 3% to 4% | ~500 patients |
| Kaftrio | 2022 | 12% | 700 – 800 patients |
| Alyftrek | 2026 | Comparable to Kaftrio | 80 to 85% of total patients |
References
- L’Avenir reporting on Mucoviscidose treatment options and reimbursement history in Belgium.